From the Wires
Radius Health to Present at BIO CEO & Investor in New York
By: Marketwired .
Feb. 8, 2013 12:38 PM
CAMBRIDGE, MA -- (Marketwire) -- 02/08/13 -- Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announced today that it will present at the 15th annual BIO CEO & Investor Conference in New York, NY. Michael Wyzga, President and CEO of Radius Health, is scheduled to present on Monday, Feb. 11, at 2:15 p.m. (EST).
Radius will provide an update on the company and its Phase 3 asset, BA058, a novel anabolic, bone-building compound under development as a potential treatment for postmenopausal women with osteoporosis at high risk for fracture. BA058-SC, an injectable form of BA058, is currently in a Phase 3 trial, and BA058-TD, is in a Phase 2 trial studying the efficacy of delivering BA058 via transdermal patch. Radius and 3M Drug Delivery Systems have an exclusive partnership agreement for development and commercialization of BA058-TD.
Event BIO CEO & Investor
The Radius presentation will be available one hour after the presentation via a webcast here: http://www.veracast.com/webcasts/bio/ceoinvestor2013/37119700.cfm
About Radius Health
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week